Safety and Efficacy of Sofosbuvir/Velpatasvir in Genotype 1-6 HCV-Infected Patients in China: Results from a Phase 3 Clinical Trial

被引：0

作者：

Wei, Lai ^{[1
]}

Xie, Qing ^{[2
]}

Huang, Yan ^{[3
]}

Wu, Shanming ^{[4
]}

Xu, Min ^{[5
]}

Tang, Hong ^{[6
]}

Cheng, Jun ^{[7
]}

Gao, Yanhang ^{[8
]}

Mou, Zhuangbo ^{[9
]}

Dou, Xiaoguang ^{[10
]}

Nan, Yuemin ^{[11
]}

Ning, Qin ^{[12
]}

Mao, Yimin ^{[13
]}

Stamm, Luisa ^{[14
]}

Lu, Sophia ^{[14
]}

Dvory-Sobol, Hadas ^{[14
]}

Mo, Hongmei ^{[14
]}

Brainard, Diana ^{[14
]}

Yang, Yongfeng ^{[15
]}

Wang, Guiqiang ^{[16
]}

Hu, Peng ^{[17
]}

Zhang, Lunli ^{[18
]}

Gao, Zhiliang ^{[19
]}

Lin, Feng ^{[20
]}

Shang, Jia ^{[21
]}

Gong, Guozhong ^{[22
]}

Li, Jun ^{[23
]}

Su, Minghua ^{[24
]}

Duan, Zhongping ^{[25
]}

Hou, Jinlin ^{[26
]}

Jia, Jidong ^{[27
]}

机构：

[1] Peking Univ, Peoples Hosp, Inst Hepatol, Beijing, Peoples R China

[2] Ruijin Hosp, Shanghai, Peoples R China

[3] Cent S Univ, Xiangya Hosp, Changsha, Hunan, Peoples R China

[4] Shanghai Publ Hlth Ctr, Shanghai, Peoples R China

[5] Guangzhou Eighth Municipal Peoples Hosp, Guangzhou, Guangdong, Peoples R China

[6] Sichuan Univ, West China Hosp, Chengdu, Sichuan, Peoples R China

[7] Capital Med Univ, Beijing Ditan Hosp, Beijing, Peoples R China

[8] Jilin Univ, Hosp 1, Changchun, Jilin, Peoples R China

[9] Jinan Infect Dis Hosp, Jinan, Shandong, Peoples R China

[10] China Med Univ, Shengjing Hosp, Shenyang, Liaoning, Peoples R China

[11] Hebei Med Univ, Hosp 3, Shijiazhuang, Hebei, Peoples R China

[12] Tongji Hosp, Shanghai, Peoples R China

[13] Shanghai Renji Hosp, Shanghai, Peoples R China

[14] Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA

[15] Second Hosp Nanjing, Nanjing, Jiangsu, Peoples R China

[16] Peking Univ, Hosp 1, Beijing, Peoples R China

[17] Chongqing Med Univ, Affiliated Hosp 2, Chongqing, Peoples R China

[18] Nanchang Univ, Affiliated Hosp 1, Nanchang, Jiangxi, Peoples R China

[19] Sun Yat Sen Univ, Affiliated Hosp 3, Guangzhou, Guangdong, Peoples R China

[20] Hainan Gen Hosp, Haikou, Hainan, Peoples R China

[21] Henan Prov Peoples Hosp, Zhengzhou, Henan, Peoples R China

[22] Cent S Univ, Xiangya Hosp 2, Changsha, Hunan, Peoples R China

[23] Nanjing Med Univ, Affiliated Hosp 1, Dept Infect Dis, Nanjing, Jiangsu, Peoples R China

[24] Shanghai Publ Hlth Clin Ctr, Shanghai, Peoples R China

[25] Capital Med Univ, Beijing Youan Hosp, Beijing, Peoples R China

[26] Nanfang Hosp, Guangzhou, Guangdong, Peoples R China

[27] Beijing Friendship Hosp, Beijing, Peoples R China

来源：

HEPATOLOGY | 2018年 / 68卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

637

引用

页码：379A / 379A

页数：1

共 50 条

[1] SAFETY AND EFFICACY OF SOFOSBUVIR/VELPATASVIR IN A GENOTYPE 1-6 HCV INFECTED POPULATION FROM SINGAPORE, MALAYSIA, THAILAND, AND VIETNAM: RESULTS FROM A PHASE 3, CLINICAL TRIAL
Lim, Seng Gee
Mohamed, Rosmawati
Phuong Le
Tee, Hoi Poh
McNabb, Brian
Lu, Sofia
Lu, Julia
McNally, John
Brainard, Diana M.
Subramanian, G. Mani
Yip, Christina Sze Man
Huang, Hai Cheng
Tan, Chee Kiat
Tanwandee, Tawesak
Kinh Nguyen Van
Piratvisuth, Teerha
GUT, 2018, 67 : A100 - A100
[2] Safety and Efficacy of Sofosbuvir/Velpatasvir in a Genotype 1-6 HCV Infected Population from Singapore, Malaysia, Thailand, and Vietnam: Results from a Phase 3, Clinical Trial
Lim, Seng Gee
Mohamed, Rosmawati
Le, Phuong
Tee, Hoi Poh
McNabb, Brian L.
Lu, Sophia
Lu, Julia
McNally, John
Brainard, Diana M.
Subramanian, Mani
Tan, Chee-Kiat
Tanwandee, Tawesak
Kinh Nguyen Van
Piratvisuth, Teerha
HEPATOLOGY, 2017, 66 : 586A - 586A
[3] EFFICACY AND SAFETY OF SOFOSBUVIR/VELPATASVIR IN GENOTYPE 3 AND 6 HCV PATIENTS IN EAST CHINA
Wang Donghui
Jiang, Suwen
Liu, Linsong
Fan, Lingyan
Hu, Airong
HEPATOLOGY, 2021, 74 : 589A - 590A
[4] Safety and Efficacy of Sofosbuvir/Velpatasvir in a Genotype 1-3 HCV Infected Russian and Swedish Population: Results from a Phase 3, Prospective Trial
Weiland, Ola
Zhdanov, Konstantin
Chulanov, Vladimir P.
McNabb, Brian L.
Lu, Sophia
Svarovskaia, Evguenia S.
McNally, John
Brainard, Diana M.
Subramanian, Mani
Abdurakhmanov, Dzhamal
Isakov, Vasily
HEPATOLOGY, 2017, 66 : 639A - 639A
[5] Safety and Efficacy of Ledipasvir/Sofosbuvir in a Genotype 1 HCV Infected Chinese Population: Results from a Phase 3, Clinical Trial
Wei, Lai
Xie, Qing
Hou, Jinlin
Tang, Hong
Ning, Qin
Cheng, Jun
Nan, Yuemin
Zhang, Lunli
Li, Jun
Jiang, Jianning
McNabb, Brian L.
Zhang, Fangqiu
Camus, Gregory
Mo, Hongmei
McNally, John
Brainard, Diana M.
Subramanian, Mani
Gong, Guozhong
Mou, Zhuangbo
Wu, Shanming
Wang, Qui-Qiang
Hu, Peng
Gao, Yanhang
Jia, Jidong
Duan, Zhongping
HEPATOLOGY, 2017, 66 : 642A - 642A
[6] A Randomized Phase 3 Trial of Sofosbuvir/Velpatasvir/Voxilaprevir for 8 Weeks Compared to Sofosbuvir/Velpatasvir for 12 Weeks in DAA-Naive Genotype 1-6 HCV-Infected Patients: The POLARIS-2 Study
Jacobson, Ira M.
Asselah, Tarik
Nahass, Ronald
Bhandari, Bal R.
Tran, Albert
Hyland, Robert H.
Stamm, Luisa M.
Dvory-Sobol, Hadas
Zhu, Yanni
Brainard, Diana M.
Subramanian, Mani
McHutchison, John G.
Shafran, Stephen
Davis, Mitchell
Stedman, Catherine A.
Lawitz, Eric
Gane, Edward J.
HEPATOLOGY, 2016, 64 (06) : 1126A - 1126A
[7] Safety and Efficacy of Velpatasvir and Sofosbuvir-based Regimens for the Treatment of HCV Genotype 1-6: Results of the HCV-TARGET Study
Landis, Charles S.
Sulkowski, Mark S.
Reau, Nancy
Lutchman, Glen A.
Vainorius, Monika
Welzel, Tania M.
Zeuzem, Stefan
Khalili, Mandana
Nelson, David R.
Lok, Anna S.
Fried, Michael W.
Terrault, Norah
HEPATOLOGY, 2017, 66 : 587A - 587A
[8] Efficacy and safety of sofosbuvir–velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial
Tetsuo Takehara
Naoya Sakamoto
Shuhei Nishiguchi
Fusao Ikeda
Tomohide Tatsumi
Yoshiyuki Ueno
Hiroshi Yatsuhashi
Yasuhiro Takikawa
Tatsuo Kanda
Minoru Sakamoto
Akihiro Tamori
Eiji Mita
Kazuaki Chayama
Gulan Zhang
Shampa De-Oertel
Hadas Dvory-Sobol
Takuma Matsuda
Luisa M. Stamm
Diana M. Brainard
Yasuhito Tanaka
Masayuki Kurosaki
Journal of Gastroenterology, 2019, 54 : 87 - 95
[9] SAFETY AND EFFICACY OF SOFOSBUVIR/VELPATASVIR/VOXILAPREVIR-BASED REGIMENS FOR THE TREATMENT OF HCV GENOTYPE 1-6: RESULTS OF THE HCV-TARGET COHORT
Zeuzem, Stefan
Sulkowski, Mark S.
Lim, Joseph K.
Morelli, Giuseppi
Khalili, Mandana
Brown, Robert S., Jr.
Ben-Ari, Ziv
Park, James S.
Reddy, K. Rajender
Shiffman, Mitchell L.
Dong, Meichen
Vainorius, Monika
Fried, Michael W.
Nelson, David R.
Terrault, Norah
HEPATOLOGY, 2019, 70 : 939A - 940A
[10] Safety and efficacy of Sofosbuvir/Velpatasvir with and without Ribavirin in genotype 3HCV-infected patients with cirrhosis
Ferret, M. B.
Pineda, J.
Panero, J. L. C.
Rodriguez, M.
Morillas, R. M.
Pascasio, J. M.
Rivero, A.
Mcnabb, B.
Zhang, G.
Camus, G.
Stamm, L.
Brainard, D.
Subramanian, M.
Carrion, J. A.
Andrade, R. J.
Amado, L. E. M.
Turnes, J.
Lens, S.
Casado, M.
Esteban, R.
JOURNAL OF HEPATOLOGY, 2018, 68 : S20 - S21

← 1 2 3 4 5 →